Centinel Spine in the News: ASC Sales Boom as Spine Procedures Migrate

Source: Becker’s ASC Review

Medical device company Centinel Spine saw its prodisc® total disc replacement sales grow 56% in the ASC setting between 2022 and 2023.

prodisc sales overall were up 55% from the year prior, at $70 million, according to the company’s year-end financial results. Centinel focuses exclusively on treating cervical and lumbar spinal disease with its total disc replacement technology platform. Its growth in the ASC space signals an overall trend of spinal procedures shifting from the inpatient to the outpatient setting…

READ THE FULL STORY ON BECKER’S ASC REVIEW

 

---

These third party links are being provided as a convenience and for informational purposes only; they do not constitute an endorsement or an approval by Centinel Spine of any of the content, views, or privacy policies of the third party site. Centinel Spine bears no responsibility for the accuracy, legality or content of the external site or for that of subsequent links. Please contact the external site for answers to questions regarding its content.

Important Note: The patient information presented is for general education purposes only. As with any spine surgery, there are potential benefits, complications, and risks associated with disc replacement and spinal fusion procedures. Individual results may vary. It is important that you discuss the possible risks and potential benefits of various procedures with your doctor prior to receiving treatment, and that you rely on your physician’s best judgment. Only your doctor can determine whether you are a suitable candidate for a specific surgical procedure.